[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S: Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut; 2000 Nov;47(5):694-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
  • BACKGROUND: More severe liver disease together with a poor response rate to alpha interferon argue for the use of more potent anti-hepatitis C virus (HCV) therapies in human immunodeficiency virus (HIV)-HCV coinfected patients, but the efficacy and safety of interferon-ribavirin combination therapy in HIV infected subjects are unknown.
  • AIM: To retrospectively evaluate the efficacy and safety of anti-HCV combination therapy in 21 HCV-HIV coinfected patients receiving antiretroviral therapy, and to access the clinical relevance of in vitro inhibition of phosphorylation by ribavirin of potent inhibitors of HIV-that is, zidovudine, stavudine, and zalcitabine.
  • PATIENTS: Twenty one patients were treated with combined antiretroviral therapy including zidovudine (n=8) or stavudine (n=13) (in association with protease inhibitors in 12).
  • All received ribavirin (1000 or 1200 mg/day) and alpha interferon (3 MU three times/week) for chronic hepatitis C infection.
  • All patients had not responded (n=20) or relapsed (n=1) after a previous six month course of alpha interferon therapy.
  • METHODS: HIV viral load (Monitor test) and CD4 cells count were measured at the beginning and every three months during and after ribavirin plus alpha interferon therapy over a mean period of 11 (1) months.
  • RESULTS: There was no significant variation in HIV viral load or CD4 cell counts after three or six months of ribavirin therapy compared with baseline values.
  • Eleven of 21 (52.4%) had initial negative HCV viraemia at three (n=10) or six (n=1) months but only six were polymerase chain reaction negative at the end of therapy, leading to rates for primary response and breakthrough of 23.8% and 28.5%, respectively.
  • Six months after completion of therapy, three patients relapsed (14.
  • Median haemoglobin concentration decreased significantly after three and six months of ribavirin therapy (p= 0.0002 and p=0.0003, respectively) leading to withdrawal of therapy in one patient.
  • (2) alpha interferon and ribavirin combination therapy induced primary and sustained virological responses in 28.5% and 14.3% of treated subjects (who were previous non-responders to interferon therapy), respectively;.
  • [MeSH-major] Antiviral Agents / therapeutic use. HIV Infections / drug therapy. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Anemia / chemically induced. CD4 Lymphocyte Count. Drug Interactions. Drug Therapy, Combination. Female. Humans. Male. Polymerase Chain Reaction / methods. Recurrence. Retrospective Studies. Treatment Outcome. Viral Load


2. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, Bertani H, Manenti F: High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol; 2001 Oct;96(10):2973-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Coinfection with hepatitis B (HBV) and hepatitis C (HCV) viruses is associated with a more severe liver disease, increased frequency in the development of hepatocellular carcinoma, and resistance to interferon (IFN) therapy when performed with the standard dosages used in single infections.
  • In the attempt to verify whether the outcome of IFN therapy in patients with hepatitis B and hepatitis C coinfection can be improved, we have planned a prospective, randomized trial with medium to high dosages of interferon three times a week for 6 months.
  • METHODS: Thirty patients with HBV-HCV coinfection, and chronic hepatitis were randomized to receive either 6 or 9 MU alpha-interferon three times a week for 6 months.
  • Patients were HBsAg positive, anti-HBe positive, HBV DNA negative by dot blot (6/30 positive by polymerase chain reaction), and anti-HCV-positive, HCV RNA positive.
  • RESULTS: Five patients treated with 9 MU IFN consistently cleared HCV RNA and HBV DNA, whereas none of those treated with 6 MU reacted in a similar fashion (p = 0.045).
  • Long term follow-up showed that none of the patients treated with high doses developed cirrhosis whereas 4/14 treated with low doses did develop cirrhosis.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / drug therapy. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11693335.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  •  go-up   go-down


3. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, Nascimben F, Zorat F, Pozzato G, Faccini L, Campanacci L: Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis; 2000 Nov;32(8):708-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal disease had usually been treated with immunosuppressive therapy, but, given the presence of viral infection, this therapy is no longer recommended.
  • In this study, we compare steroid vs interferon therapy in a group of patients affected by hepatitis C virus-positive cryoglobulinaemic glomerulonephritis in the stationary phase.
  • PATIENTS/METHODS: The diagnosis of cryoglobulinaemic glomerulonephritis was made bearing in mind standard criteria.
  • Patients were randomly assigned to 2 groups receiving oral prednisone 0.2 mg/kg/die for 6 months (6 patients, group A) or lymphoblastoid interferon 3 MU, three times a week for 6 months [7 patients, group B).
  • Hepatitis C virus-RNA was determined by reverse transcription-polymerase chain reaction and hepatitis C virus genotype according to Okamoto.
  • Hepatitis C virus-RNA quantitation was performed by competitive polymerase chain reaction.
  • All genotypes of hepatitis C virus were found with a prevalence of Type 1b.
  • At the end of the treatment, all patients in both groups relapsed.
  • CONCLUSIONS: Interferon seems to be an effective drug in the treatment of cryoglobulinaemic glomerulonephritis, but dosage and length of treatment still need to be addressed by large multicentre studies.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antiviral Agents / therapeutic use. Cryoglobulinemia / drug therapy. Cryoglobulinemia / virology. Glomerulonephritis / drug therapy. Glomerulonephritis / virology. Hepatitis C / complications. Interferon-alpha / therapeutic use. Prednisone / therapeutic use
  • [MeSH-minor] Aged. Female. Genotype. Hepacivirus / genetics. Humans. Immunophenotyping. Male. Middle Aged. Prospective Studies. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142582.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; VB0R961HZT / Prednisone
  •  go-up   go-down


Advertisement
4. Boucher E, Guyader D, Jacquelinet S, Andre P, Mendler MH, Turlin B, Canva V, Nousbaum JB, Bernard PH, Nouel O, Raabe JJ, Dao T, Gasser P, Verger P, Boutin J, Bergerault P, Joram F, Colmar P, Messner M, Brissot P, Deugnier Y: Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Dig Liver Dis; 2000 Jan-Feb;32(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
  • They were all given: interferon alpha-2a (3 MU subcutaneously thrice a week) and ursodeoxycholic acid (10 mg/kg/day) for 9 months.
  • At month 9, biochemical responders only were randomized into ursodeoxycholic acid treatment or placebo for 12 additional months (double blind study).
  • RESULTS: At the end of interferon therapy, 71 patients (37%) were virological responders and 107 (56%) patients were biochemical responders and were randomized: 54 into the ursodeoxycholic acid group and 53 into the placebo group.
  • CONCLUSION: Continuation of ursodeoxycholic acid therapy after withdrawal of interferon in patients with end-of-treatment response did not result in any significant improvement either in the maintenance of response to interferon or in liver histology.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cholagogues and Choleretics / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Double-Blind Method. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Female. Hepacivirus / genetics. Hepacivirus / immunology. Hepatitis C Antibodies / analysis. Humans. Male. Middle Aged. Prospective Studies. RNA, Viral / analysis. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975752.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cholagogues and Choleretics; 0 / Hepatitis C Antibodies; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 724L30Y2QR / Ursodeoxycholic Acid; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


5. Witzig TE, Wahner-Roedler DL: Heavy chain disease. Curr Treat Options Oncol; 2002 Jun;3(3):247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heavy chain disease.
  • The heavy chain diseases (HCDs) are rare B-cell malignancies that are distinguished by the production of a monoclonal immunoglobulin heavy chain (HC) without an associated light chain by the malignant B-cells.
  • There are three types of HCD defined by the class of immunoglobulin (Ig) HC produced: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD).
  • Alpha-HCD is the most common and occurs most commonly as intestinal malabsorption in a young adult from a country bordering the Mediterranean Sea.
  • Treatment consists of antibiotics and improved nutrition and hygiene.
  • If there is no response to antibiotics or if aggressive non-Hodgkin's lymphoma (NHL) is diagnosed, the patient should be treated with chemotherapy.
  • Gamma- and mu-HCD are rare and essentially are found in patients with a B-cell NHL that produces an abnormal Ig heavy chain.
  • These patients occasionally may be diagnosed with a monoclonal gammopathy of undetermined significance (MGUS).
  • Patients with MGUS with NHL should be administered chemotherapy.
  • Screening the serum and urine of patients with lymphoplasmacytoid NHL would likely identify more patients with gamma- or mu-HCD.
  • [MeSH-major] Heavy Chain Disease / therapy
  • [MeSH-minor] Adult. Aged. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Incidence. Middle Aged. Radiotherapy

  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for heavy chain disease .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Rheumatol. 2000 Jan;12(1):65-70 [10647957.001]
  • [Cites] Histopathology. 1990 Jul;17(1):7-17 [2227833.001]
  • [Cites] J Clin Gastroenterol. 1998 Jul;27(1):85-9 [9706780.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):231-4 [9858149.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):359-65 [9401282.001]
  • [Cites] Rev Prat. 1993 Feb 1;43(3):317-20 [8502962.001]
  • [Cites] Mayo Clin Proc. 1987 Aug;62(8):719-31 [3110508.001]
  • [Cites] Clin Chem. 1994 Apr;40(4):664 [8149622.001]
  • [Cites] Arch Pathol Lab Med. 1986 Oct;110(10):893-6 [3094476.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):20-4 [8313111.001]
  • [Cites] Eur J Haematol. 1995 Mar;54(3):202-4 [7720844.001]
  • [Cites] J Am Acad Dermatol. 1990 Nov;23(5 Pt 2):988-91 [2121807.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):18-22 [8554029.001]
  • [Cites] Am J Med. 1990 Oct;89(4):483-90 [2145762.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):737-42 [10792277.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):653-5 [7819086.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):8-14 [9210703.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Gastroenterol Clin Biol. 1985 Jun-Jul;9(6-7):472-9 [3926586.001]
  • [Cites] Hum Pathol. 1984 Feb;15(2):122-9 [6421714.001]
  • [Cites] Am J Hematol. 1992 May;40(1):56-60 [1566748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2463-8 [9482908.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):427-36 [6814232.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):400-6 [7674998.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1375-82 [8021727.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1281-94 [10626151.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] Z Gastroenterol. 1995 Apr;33(4):209-13 [7793120.001]
  • [Cites] Clin Chem. 1981 Feb;27(2):331-3 [7460288.001]
  • [Cites] Mayo Clin Proc. 1981 Jul;56(7):439-51 [6789012.001]
  • [Cites] Recent Results Cancer Res. 1978;64:271-6 [104370.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1251-6 [2920354.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Gut. 1978 Jul;19(7):627-31 [98395.001]
  • (PMID = 12057070.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 36
  •  go-up   go-down


6. Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology; 2003 Apr;37(4):756-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
  • To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 101 consecutive patients were treated with 6 MU of interferon alfa 2b 3 times weekly for 24 months.
  • During the 68-month study, 30 patients (30%) had a sustained response (i.e., normal serum transaminase levels and undetectable hepatitis B virus DNA by non-polymerase chain reaction [PCR] assays), and 15 cleared serum surface antigen.
  • Twenty-five nonresponders, 16 relapsers, and 30 who discontinued treatment were considered treatment failures.
  • Multivariate analysis predicted a sustained response for young age (odds ratio, 0.94; 95% confidence interval, 0.89-0.99; P =.041) and high pretreatment serum levels of immunoglobulin M (IgM) anti-hepatitis B core antigen (HBc) (odds ratio, 4.52; 95% confidence interval, 1.63-12.5; P =.004).
  • Liver disease progressed in none of the sustained responders but in 16 with treatment failure (0% vs. 22%, P =.002); hepatocellular carcinoma (HCC) developed with similar frequency in both groups (7%).
  • Overall, estimated 8-year complication-free survival was longer for the 30 sustained responders than the 71 patients with treatment failure (90% vs. 60%, P <.001), but 8-year patient survival was similar in the 2 groups (100% and 90%).
  • In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg-negative chronic hepatitis B.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis B e Antigens / analysis. Hepatitis B, Chronic / drug therapy. Hepatitis B, Chronic / immunology. Interferon-alpha / administration & dosage
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Cohort Studies. DNA, Viral / metabolism. Drug Administration Schedule. Female. Follow-Up Studies. Hepatitis B virus / genetics. Humans. Liver / pathology. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis E.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2003 Sep;38(3):779-80; author reply 780 [12939609.001]
  • (PMID = 12668967.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


7. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc; 2004 Jul-Aug;36(6):1831-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
  • INTRODUCTION: Hepatitis C Viral (HCV) infection is the leading cause of chronic liver disease in end-stage renal disease patients (ESRD).
  • The main aim of this pilot study was to assess the efficacy of combined alpha-interferon (alpha-IFN) and ribavirin treatment of HCV hemodialysis (HDx) patients, by comparing the sustained virological response to that obtained by local historical data on treatment with alpha-IFN alone.
  • A secondary aim was to establish the optimal therapeutic dose of ribavirin in this regimen.
  • They received combination therapy with 3 million units (MU) of alpha-IFN and 200 mg of ribavirin three times a week.
  • RESULTS: Six of the nine patients who were treated for 24 weeks (66%) became HCV-PCR-negative by the end of the treatment period.
  • They continued to have a sustain virologic response at 6 months after the cessation of therapy.
  • Six of the 11 patients (55%) who were treated for 48 weeks became HCV-PCR-negative at the end, and at 6 months after cessation of treatment.
  • Of the first six responders, 4 (66%) maintained a sustained virologic response at 1 year postcessation of therapy.
  • No side effects were reported for a ribavirin dose of 200 mg three times a week.
  • CONCLUSION: This pilot study suggests that combination treatment for 24 weeks and 48 weeks with 3 MU alpha-IFN and 200 mg ribavirin three times a week, elicited a sustained virologic response in HDx patients with HCV infection better than IFN alone with minimal side effects.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Renal Dialysis / adverse effects. Ribavirin / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Humans. Male. Middle Aged. Pilot Projects. Polymerase Chain Reaction. Treatment Outcome


8. Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J: [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Vnitr Lek; 2009 Nov;55(11):1089-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
  • [Transliterated title] Vymizení nefrotického syndromu a zlepsení funkce ledvin u nemocné s light chain deposition disease po vysokodávkované chemoterapii s autologní transplantací kmenových krvetvorných bunek. Popis prípadu a prehled literatury.
  • Light chain deposition disease (LCDD) damages most frequently kidneys, and less frequently other organs.
  • Renal biopsy specimen revealed the diagnosis of LCDD.
  • These findings confirmed the diagnosis of multiple myeloma (MM) Durie Salmon stage IB with LCDD.
  • The patient was initially treated with 4 cycles of VAD (vinkristine, adriamycine, dexamethasone) chemotherapy with no response.
  • Followed collection of peripheral haematopoietic stem cells and later high dose chemotherapy with reduced dose of melphalan 140 mg/sqm and autologous peripheral haematopoietic stem cells transplantation.
  • High dose therapy was complicated by with deterioration of renal function, creatinine increased to 600 micromol/l.
  • Follow-up examination one month after high dose chemotherapy showed complete remission, that was confirmed by further examinations.
  • In the course of the first year after high dose chemotherapy renal function gradually improved and nephrotic syndrome completely disappeared (complete kidney remission).
  • Three years after high dose chemotherapy the patient is still in complete remission of multiple myeloma and free of nephrotic syndrome, with slightly increased creatinine (160 micromol/l) that, nevertheless, has had an improving tendency over last 3 years.
  • The present case study illustrates accomplishment of complete haematological remission with high dose chemotherapy followed by autologous haematopoietic stem cells transplantation despite complete resistance of the disease to the standard chemotherapy VAD in a patient with MM and LCDD.
  • We draw the reader's attention to the possibility of nephrotoxic effects of high dose melphalan (post conditioning renal insufficiency) in patients with nephrotic syndrome caused by light chain deposits as AL-amyloid or amorphous light chains deposits (LCDD)and we document the importance of plasma free light chain detection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoglobulin Light Chains / immunology. Multiple Myeloma / therapy. Nephrotic Syndrome / physiopathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Kidney / pathology. Melphalan / administration & dosage. Melphalan / adverse effects. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017442.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  • [Number-of-references] 48
  •  go-up   go-down


9. Lourenço GJ, Lorand-Metze I, Delamain MT, Miranda EC, Kameo R, Metze K, Lima CS: Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma; 2010 Dec;51(12):2215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma.
  • We examined the influence of the glutathione S-transferase mu 1 (GSTM1), theta 1 (GSTT1), and pi 1 (GSTP1) polymorphisms, which are involved in the metabolism of alkylating agents and anthracyclines, on the outcome of patients with Hodgkin lymphoma (HL) treated with conventional chemotherapy.
  • Genomic DNA from 125 consecutive cases was analyzed by polymerase chain reaction and enzymatic digestion for polymorphism determination.
  • The GSTM1 undeleted genotype was associated with more advanced tumor stage and worse disease-free survival.
  • In contrast, higher toxicity of chemotherapy was attributed to absence of the GSTT1 gene.
  • [MeSH-major] Glutathione S-Transferase pi / genetics. Glutathione Transferase / genetics. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Polymorphism, Genetic


10. Adam Z, Nedbálková M, Krejcí M, Pour L, Husek K, Veselý K, Cermáková Z, Krivanová A, Mayer J, Hájek R: [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)]. Vnitr Lek; 2010 Mar;56(3):240-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
  • [Transliterated title] Více nez 10 let trvající kompletní remise monoklonální gamapatie nejistého významu a vymizení nefrotického syndromu vzniklého na podkladne light chain deposition disease po lécbe vinkristinem, adriamycinem a vysokými dávkami dexametazonu (VAD).
  • Light chain deposits in the form of amorphous material (light chain deposition disease) damage most frequently kidneys and, less frequently, they affect other organs.
  • The incidence of light chain deposition disease is much lower than that of AL-amyloidosis.
  • Symmetrical swelling of both legs, swelling of the eye lids, erythrocyturia and nephrotic proteinuria were the first signs of light chain deposition disease in our patient.
  • The disease was diagnosed from kidney biopsy performed at the stage of advanced nephrotic syndrome with reduced filtration.
  • However, 2 months after the completion of chemotherapy, the immunofixation electrophoresis had become negative and thus complete haematological treatment response (remission) was achieved.
  • Proteinuria declined below 1 g/l and no erythrocyturia was present 4 years post-treatment.
  • Proteinuria declined to 0.19 g/I, i.e., normal values, 9 years post-treatment completion.
  • Regular follow-ups in patients with MGUS should seek to identify not only whether MGUS is transforming into malignant disease but also whether monoclonal immunoglobulin is damaging the organism.
  • Treatment of patients with monoclonal immunoglobulin-associated damage should be initiated early as the restoration of the affected organs function (organ treatment response) after complete haematological remission is only gradual.
  • At present, treatment regimes with high-dose dexamethasone are recommended for patients with primary systemic AL-amyloidosis.
  • We believe that the same approach is suitable for the treatment of light chain deposition disease in MGUS patients.
  • [MeSH-major] Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Immunoglobulin Light Chains / analysis. Monoclonal Gammopathy of Undetermined Significance / complications. Monoclonal Gammopathy of Undetermined Significance / drug therapy. Nephrotic Syndrome / complications. Nephrotic Syndrome / immunology. Vincristine / administration & dosage
  • [MeSH-minor] Aged. Drug Therapy, Combination. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394211.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Zhong SL, Zhou S, Chen X, Huang M: Rapid determination of common mutations in glutathione S-transferase gene by PCR-based methods in healthy Chinese. Clin Chim Acta; 2006 Feb;364(1-2):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All these mutations, in particular those in class mu, pi and theta GST, are likely to contribute to interindividual differences in responses to xenobiotics including response to chemotherapy and associated with altered disease.
  • [MeSH-major] Glutathione Transferase / genetics. Mutation. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Chim Acta. 2006 Aug;370(1-2):203 [16814272.001]
  • (PMID = 16098500.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


12. Wang J, Huang C, Wei XY, Qi DL, Gong LQ, Mu HY, Yao Q, Li K: Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy. Chin Med J (Engl); 2008 Nov 20;121(22):2234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy.
  • BACKGROUND: Although antiangiogenesis therapy plays an important role in anti-neoplastic treatment with its recognized efficacy and slight adverse effect, there is no prospective clinical trial to define ideal markers for predicting efficacy of antiangiogenic therapy.
  • This study was undertaken to investigate the changes of activated circulating endothelial cells (aCECs) and survivin after anti-angiogenesis therapy and their significance in predicting the efficacy of the therapy.
  • METHODS: Patients of non-small cell lung cancer (NSCLC) treated with chemotherapy with or without Endostar were observed.
  • The amount of activated CECs was detected by flow cytometry, and the expression of survivin mRNA was determined by real-time polymerase chain reaction (PCR).
  • RESULTS: After treatment, the amount of activated CECs decreased significantly in clinical benefit cases (P = 0.021 in chemotherapy alone, P = 0.001 in chemotherapy plus Endostar), increased in disease progressive cases (P = 0.015 in chemotherapy alone, but P = 0.293 in chemotherapy with Endotatar).
  • After therapy, the expression of survivin mRNA decreased in clinical benefit cases (P = 0.001) and increased in disease progressive cases (P = 0.018).
  • A positive correlation was found between activated CECs and survivin in the chemotherapy group pre- and post-therapy (P = 0.001 and 0.021, respectively), but only in the chemotherapy with Endostar group pre-therapy (P = 0.030) rather than post-therapy.
  • A positive correlation was found between the decreased activated CECs after therapy and time to progression (TTP) (r = 0.322, P = 0.012); a negative correlation was found between the amount of survivin mRNA in serum post-therapy and TTP (r = -0.291, P = 0.048).
  • Their combination can evaluate more accurately the efficacy of antiangiogenic therapy of NSCLC.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Endothelial Cells / drug effects. Lung Neoplasms / drug therapy. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Endostatins / therapeutic use. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080323.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / BIRC5 protein, human; 0 / Endostatins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / endostar protein
  •  go-up   go-down


13. Reddy PJ, Aksoy MO, Yang Y, Li XX, Ji R, Kelsen SG: Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells. COPD; 2008 Feb;5(1):5-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CXC chemokines, IP-10/CXCL10 and IL-8/CXCL8, play a role in obstructive lung disease by attracting Th1/Tc1 lymphocytes and neutrophils, respectively.
  • Cytokine treatment (TNF-alpha, IL-1beta and IFN-gamma) increased IP-10 and IL-8 protein and mRNA levels.
  • Fluticasone (0.1 nM to 1 microM) increased IP-10 but reduced IL-8 protein release without changing IP-10 mRNA levels assessed by real time RT-PCR.
  • The combination of salmeterol (1 micro M) and cilomilast (1-10 mu M) reduced IP-10 but had no effect on IL-8 protein.
  • In human airway epithelial cells, inhibition by salmeterol of fluticasone-enhanced IP-10 release may be an important therapeutic effect of the LABA/ICS combination not present when the two drugs are used separately.
  • [MeSH-major] Albuterol / analogs & derivatives. Chemokine CXCL10 / antagonists & inhibitors. Epithelial Cells / metabolism. Gene Expression / drug effects. Nitriles / pharmacology. RNA / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Adrenergic beta-Agonists / pharmacology. Asthma / drug therapy. Asthma / metabolism. Asthma / pathology. Carboxylic Acids / pharmacology. Cells, Cultured. Cyclohexanecarboxylic Acids. Enzyme-Linked Immunosorbent Assay. Humans. Interleukin-8 / antagonists & inhibitors. Interleukin-8 / biosynthesis. Interleukin-8 / genetics. Phosphodiesterase Inhibitors. Reverse Transcriptase Polymerase Chain Reaction. Salmeterol Xinafoate

  • Hazardous Substances Data Bank. ALBUTEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259970.001).
  • [ISSN] 1541-2555
  • [Journal-full-title] COPD
  • [ISO-abbreviation] COPD
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Carboxylic Acids; 0 / Chemokine CXCL10; 0 / Cyclohexanecarboxylic Acids; 0 / Interleukin-8; 0 / Nitriles; 0 / Phosphodiesterase Inhibitors; 63231-63-0 / RNA; 6EW8Q962A5 / Salmeterol Xinafoate; 8ATB1C1R6X / Cilomilast; QF8SVZ843E / Albuterol
  •  go-up   go-down


14. Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, Cruz PE, Roncal CA, Glushakova OY, Chiodo VA, Atkinson MA, Hauswirth WW, Flotte TR, Rodriguez-Iturbe B, Johnson RJ: IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol; 2005 Dec;16(12):3651-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease.
  • Whereas short-term administration of IL-10 has shown benefit in acute glomerulonephritis, no studies have addressed the potential benefits of IL-10 in chronic renal disease.
  • Four weeks after injection, IL-10 levels in serum were measured by ELISA, and chronic renal disease was induced by a 5/6 nephrectomy (n = 6 in each group).
  • Eight weeks later, rats were killed and renal tissue was obtained for RNA, protein, and immunohistochemical analysis.
  • Serum levels of IL-10 were 12-fold greater in the rAAV1-IL-10 group by 4 wk after rAAV1-IL-10 administration (345 +/- 169 versus 28 +/- 15 pg/ml; P = 0.001), and levels were maintained throughout the experiment. rAAV1-IL-10 treatment resulted in less proteinuria (P < 0.05), lower serum creatinine (P < 0.05), and higher creatinine clearances (P < 0.01) compared with rAAV1-GFP-treated rats.
  • The reduction in inflammatory cells was associated with a significant reduction in glomerulosclerosis and interstitial fibrosis.
  • It is concluded that IL-10 blocks inflammation and improves renal function in this model of chronic renal disease.
  • The feasibility of long-term overexpression of a gene using the AAV serotype 1 vector system in a model of renal disease is also demonstrated.
  • [MeSH-major] Chemokines / metabolism. Interleukin-10 / blood. Interleukin-10 / pharmacology. Kidney Failure, Chronic / drug therapy. Kidney Failure, Chronic / pathology. Nephritis, Interstitial / pathology
  • [MeSH-minor] Animals. Biopsy, Needle. Cytokines / drug effects. Cytokines / metabolism. Disease Models, Animal. Fibrosis / drug therapy. Fibrosis / pathology. Gene Expression Regulation. Immunohistochemistry. Kidney Function Tests. Male. Proteinuria / physiopathology. RNA, Messenger / analysis. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251240.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-52121; United States / NIDDK NIH HHS / DK / DK-64322; United States / NHLBI NIH HHS / HL / HL-68607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / RNA, Messenger; 130068-27-8 / Interleukin-10
  •  go-up   go-down


15. Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H, Veierød MB, Ellingsen I, Seljeflot I: The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thromb Haemost; 2004 Jun;91(6):1097-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate the effect of long-term diet and very long chain n-3 fatty acids (VLC n-3) intervention on plasma coagulation factor VII (FVII), choline-containing phospholipids (PC) and triglycerides (TG), especially related to the R353Q polymorphism of the FVII gene.
  • The subjects were randomly allocated to receive placebo capsules (corn oil) (control), placebo capsules and dietary advice ("Mediterranean type" diet), VLC n-3 capsules, or VLC n-3 capsules and dietary advice combined.
  • Diet intervention was followed by a significant reduction of 5.1% in the levels of FVIIag and 2.4 mU/ml in FVIIa (95% CI -7.4, -2.9, and -3.8, -1.1, respectively) (both p<0.001) compared to the no diet group, independent of genotype.
  • Dietary advice towards a "Mediterranean type" diet, but not VLC n-3 supplementation, was shown to reduce the levels of FVIIag and FVIIa after 6 months, independent of genotype.
  • [MeSH-major] Dietary Supplements. Factor VII / drug effects. Factor VII / genetics. Fatty Acids, Omega-3 / pharmacology. Phospholipids / blood. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aged. Arteriosclerosis / drug therapy. Coronary Disease / prevention & control. Humans. Male. Mutation, Missense. Phosphatidylcholines / blood. Risk. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175795.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Phosphatidylcholines; 0 / Phospholipids; 0 / Triglycerides; 9001-25-6 / Factor VII
  •  go-up   go-down


16. Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, Ronco P: Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol; 2008 Sep;3(5):1339-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum.
  • BACKGROUND AND OBJECTIVES: Since the first description of pathology of the kidney in Waldenström disease in 1970, there have been few reports on kidney complications of IgM-secreting monoclonal proliferations.
  • Here, we aimed to revisit the spectrum of renal lesions occurring in patients with a serum monoclonal IgM.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fourteen patients with a circulating monoclonal IgM and a kidney disease related to B cell proliferation were identified retrospectively.
  • Demographic, clinical, and laboratory data were assessed for each patient at the time of kidney biopsy.
  • For five patients, the diagnosis of monoclonal IgM preceded the kidney disease by 28.8 mo (range 12 to 60).
  • Seven patients had Waldenström disease, two had a small B cell non-Hodgkin lymphoma, one had an IgM-excreting multiple myeloma, one had a marginal zone B cell lymphoma, and three had an IgM-related disorder.
  • Renal lesions included (1) intracapillary monoclonal deposits disease with granular, electron-dense IgM thrombi occluding capillary lumens (5);.
  • (3) lambda light chain amyloidosis (2) associated with mu deposits in one patient;.
  • Remission of the nephrotic syndrome was attained in three of seven patients, and renal function improved after chemotherapy.
  • CONCLUSIONS: Although renal complications of IgM proliferations are rare, a wide spectrum of kidney lesions is observed, without correlation with the type of hematologic disorder.
  • [MeSH-major] Antibodies, Monoclonal / analysis. B-Lymphocytes / immunology. Cell Proliferation. Immunoglobulin M / analysis. Kidney Diseases / immunology. Lymphoproliferative Disorders / immunology
  • [MeSH-minor] Aged. Amyloidosis / immunology. Female. Glomerulonephritis, Membranoproliferative / immunology. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell, Marginal Zone / immunology. Male. Middle Aged. Multiple Myeloma / immunology. Nephrotic Syndrome / immunology. Retrospective Studies. Treatment Outcome. Waldenstrom Macroglobulinemia / immunology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Am J Nephrol. 1985;5(1):53-8 [3918448.001]
  • [Cites] Am J Kidney Dis. 2004 May;43(5):e23-8 [15112195.001]
  • [Cites] Crit Care. 2004 Aug;8(4):R204-12 [15312219.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6542-6 [2118650.001]
  • [Cites] N Engl J Med. 1991 Jun 27;324(26):1845-51 [1904132.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):914-20 [8487054.001]
  • [Cites] Am J Hematol. 1994 Feb;45(2):171-6 [8141123.001]
  • [Cites] Clin Sci (Lond). 1994 Nov;87(5):487-91 [7874834.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jun;12(6):1256-9 [9198063.001]
  • [Cites] Clin Nephrol. 1998 May;49(5):325-7 [9617499.001]
  • [Cites] Nephrol Dial Transplant. 1998 Oct;13(10):2630-2 [9794573.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):749-57 [15806478.001]
  • [Cites] Clin Nephrol. 2005 Nov;64(5):396-9 [16312271.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):908-14 [16632032.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):e3-9 [16797380.001]
  • [Cites] Nephrol Dial Transplant. 2007 Feb;22(2):627-30 [17164317.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1342-50 [17699367.001]
  • [Cites] J Hypertens. 2007 Sep;25(9):1751-62 [17762635.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):122-5 [10665924.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):880-3 [11054074.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1058-66 [11287977.001]
  • [Cites] Am J Kidney Dis. 2001 Aug;38(2):395-9 [11479168.001]
  • [Cites] Nephron. 2002 Jul;91(3):512-5 [12119489.001]
  • [Cites] Nephron. 2002 Oct;92(2):452-5 [12218329.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):541-5 [12657941.001]
  • [Cites] Medicine (Baltimore). 2008 Mar;87(2):99-109 [18344807.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] N Engl J Med. 1970 Jul 16;283(3):123-9 [4987279.001]
  • [Cites] Arch Intern Med. 1975 Jan;135(1):40-5 [803364.001]
  • [Cites] Nephron. 1984;38(3):156-62 [6436718.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):679-85 [14602248.001]
  • (PMID = 18632851.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin M
  • [Other-IDs] NLM/ PMC2518806
  •  go-up   go-down


17. Cheng PN, Chow NH, Hu SC, Young KC, Chen CY, Jen CM, Chang TT: Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Dig Liver Dis; 2002 Dec;34(12):851-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
  • BACKGROUND: Interferon a with ribavirin combination therapy is effective but still unsatisfactory in the treatment of patients with interferon-relapsed chronic hepatitis C.
  • AIMS: To compare, in a randomized, double blind, placebo-controlled study, high-dose interferon-alpha2b with or without ribavirin in the treatment for interferon-relapsers.
  • PATIENTS: A total of 52 patients with interferon-relapsed chronic hepatitis C were randomly assigned to receive 24-week treatment with interferon-alpha2b (6 MU three times per week) combined with either ribavirin (1,000 to 1,200 mg per day) or a matched placebo and then followed for an additional 24 weeks.
  • METHODS: Hepatitis C virus RNA was detected by reverse-transcription polymerase chain reaction.
  • Genotyping was performed by reverse hybridization assay RESULTS: At the end of treatment, no detectable hepatitis C virus RNA levels were observed in 92% (24/26) of patients on interferon alpha2b/ribavirin and 81% (21/26) of patients on interferon alpha2b/placebo.
  • Patients who received interferon-alpha2b/ribavirin treatment and in whom no hepatitis C virus RNA was detected at 4th week after treatment had 90% chance to achieve sustained virological response.
  • CONCLUSIONS: High-dose interferon-alpha2b plus ribavirin treatment is highly effective in interferon-relapsed patients.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis C, Chronic / drug therapy. Interferon-alpha / administration & dosage. Ribavirin / administration & dosage
  • [MeSH-minor] Adult. Double-Blind Method. Drug Administration Schedule. Drug Therapy, Combination. Female. Hepacivirus / genetics. Humans. Male. Middle Aged. RNA, Viral / analysis. Recurrence

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643293.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 49717AWG6K / Ribavirin
  •  go-up   go-down


18. Adam Z, Pour L, Krejcí M, Zahradová L, Krivanová A, Mardová J, Kovárová L, Stepánková S, Moulis M, Kren L, Veselý K, Svobodová I, Germáková Z, Nedbálková M, Mayer J, Hájek R: [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. Vnitr Lek; 2010 Mar;56(3):190-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
  • PATIENTS: Fifteen patients with light chain deposits in the form of AL-amyloidosis and 2 patients with light chain deposition as amorphous matter (light chain deposition disease) were treated at our clinic as of 1999.
  • Median age at the diagnosis was 63 (34-77) years.
  • The light chain deposition caused: nephrotic syndrome in 12 (70%) patients, renal insufficiency with reduced filtration in 4 (23%) patients, cardiomyopathy in 4 (23%) patients, hepatosplenomegaly in 2 (12%) patients, manifest coagulopathy in 2 (12%) patients, periorbital hematoma in 2 (12%) patients, visceral and somatic neuropathy in 2 (12%) patients.
  • Treatment with high-dose dexamethasone in combination with adriamycin and vincristine (VAD) or cyclophosphamide (CAD orjust CD) was used in 11 patients.
  • In 4 patients, therapy was completed with high-dose chemotherapy and autologous transplantation; complete haematological and organ treatment response was achieved in all 4 patients with remission lasting 113+, 87+, 50, 45+ months.
  • Of the remaining 7 patients in whom high-dose dexamethasone therapy was not completed with high-dose chemotherapy, 3 achieved complete haematological remission (CR) and very good partial remission (VGPR), with 2 patients achieving complete organ treatment response.
  • PR with no organ treatment response was achieved in other 2 patients and 2 patients died during the treatment.
  • Therapy with prednisone and alkylating cytostatics was used in 2 patients with serious organ damage, both patients died after a short period of time due to the disease and thus treatment response cannot be evaluated.
  • Two patients underwent a total of 5 and 6 cycles of this treatment with PR effect and plateau after the previous decline of monoclonal immunoglobulin concentrations.
  • Treatment combination of bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) was used in three patients.
  • Just one of the 3 female patients has been followed up for more than 12 months and so it is possible to evaluate organ treatment response in this patient; nephrotic syndrome ceased, meaning that organ CR has been achieved.
  • CONCLUSION: Early diagnosis (before severe organ damage occurs) enables administration of aggressive treatment (high-dose chemotherapy and autologous transplantation) with the outlook of complete haematological and organ treatment response.
  • New drugs thalidomide and bortezomib further expand treatment armamentarium; according to our limited experience and published information, bortezomib may be considered as very effective and well tolerated agent suitable, in combination, for patients with the diagnosis of AL-amyloidosis.
  • [MeSH-major] Amyloidosis / drug therapy. Boronic Acids / administration & dosage. Pyrazines / administration & dosage. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394205.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 98
  •  go-up   go-down






Advertisement